[Avastin® (Bevacizumab): Off-label use in cancer therapy]

Geiger-Gritsch, S. (2007): [Avastin® (Bevacizumab): Off-label use in cancer therapy]. HTA-Newsletter 58: p. 2.

Preview

PDF (HTA-Newsletter 58) - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
336kB

Item Type:	HTA Newsletter Item
Keywords:	Avastin (bevacizumab), angiogenesis inhibitor, vascular endothelial growth factor (VEGF), off-label use, cancer therapy, non-small cell lung cancer (NSCLC), renal cell carcinoma, non-colorectal cancer, adverse effects, risks, approval
Subjects:	QW Microbiology. Immunology WF Respiratory system WJ Urogenital system > WJ 300-378 Kidney
Related URLs:	http://hta.lbg.ac.at/en/content.php?iMenuID=69
References:	1. BCBS/USA 2006: Off-Label Uses of Bevacizumab: Breast and Lung Cancer Indications. URL: http://www.bcbs.com/betterknowledge/tec/vols/21/21_08.pdf. 2. BCBS/USA 2006: Off-Label Uses of Bevacizumab: Renal Cell Carcinoma and Other Miscellaneous Non-Colorectal Cancer Indications. URL: http://www.bcbs.com/betterknowledge/tec/vols/21/21_09.pdf. 3. Zhu X et al. 2007: Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-analysis. Am J Kidney Dis 49: 186-93.
Language:	German
Number:	58
Deposited on:	18 Jan 2008 17:57
Last Modified:	15 Jul 2020 17:21

Repository Staff Only: item control page